Clinical Trial Update: Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating rifaximin to treat gastrointestinal toxicities related to pertuzumab-based therapy in patients with stage I-III HER2-positive …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: Mayo Clinic | Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Phase 2 | Status: TERMINATED | Results posted: 2025-08-07